Investigation of responsiveness indices of generic and specific measures of health related quality of life in patients with osteoporosis

J Back Musculoskelet Rehabil. 2014;27(4):391-7. doi: 10.3233/BMR-140459.

Abstract

Purpose: To compare responsiveness Short Form-36 (SF-36), Nottingham Health Profile (NHP), and QUALEFFO-41 scales in patients diagnosed with osteoporosis.

Methods: A number of 70 osteoporosis patients who were in their menopause period at least for three years were enrolled in our study. The patients completed Short Form-36 (SF-36), Nottingham Health Profile (NHP), and QUALEFFO-41 scales during pretreatment period and one year after the termination of the treatment. Reponsiveness was compared between questionnaires using standardized responsiveness mean (SRM), the effect size (ES), and Guyatt's method.

Results: All scales revealed statistically significant improvement after the treatment. Upon this finding, calculations related with responsiveness indices for SF-36 (Physical Health and Mental Health), NHP (Total point), and QUALEFFO-41 (Total point) demonstrated highly responsive. ES=1.67 and 1.55, SRM=1.55 and 1.85, Guyatt value=2.20 and 1.91 for SF-36 Physical Health and Mental Health. ES=1.35, SRM=1.35, Guyatt value=1.72 for NHP. QUALEFFO-41's ES=2.56, SRM=4.32 and Guyatt value=2.31.

Conclusion: Osteoporosis specific scale as QUALEFFO-41, gives more specific information about the quality of life of osteoporotic patients. If patients with osteoporosis will be compared with other diseases regarding quality of life, then SF-36, one scale was used to evaluate general quality life of such patients, should be preferred against NHP.

Keywords: Nottingham Health Profile; Osteoporosis; QUALEFFO-41; Short Form-36; quality of life scales.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alendronate / therapeutic use
  • Bone Density Conservation Agents / therapeutic use
  • Calcium / therapeutic use
  • Dietary Supplements
  • Female
  • Health Surveys
  • Humans
  • Middle Aged
  • Osteoporosis, Postmenopausal / drug therapy*
  • Osteoporosis, Postmenopausal / psychology*
  • Patient Outcome Assessment*
  • Quality of Life / psychology*
  • Reproducibility of Results
  • Surveys and Questionnaires*
  • Vitamin D / therapeutic use

Substances

  • Bone Density Conservation Agents
  • Vitamin D
  • Calcium
  • Alendronate